PHUONG WEINBERGER: Open Payments
NPI 1689058109 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,139 in 140 payments from 18 companies in 2025. Trend: 2023 $869 · 2024 $2,770 · 2025 $3,139
Food & beverage: $3,139
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 29 | $605 |
| ABBVIE INC. | 25 | $478 |
| Lilly USA, LLC | 9 | $282 |
| Madrigal Pharmaceuticals | 10 | $255 |
| Celltrion USA Inc. | 13 | $217 |
| QOL Medical, LLC | 7 | $204 |
| GENZYME CORPORATION | 4 | $189 |
| Aimmune Therapeutics, Inc. | 7 | $180 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $146 |
| Janssen Scientific Affairs, LLC | 1 | $130 |
Products named: TREMFYA, DUPIXENT, OMVOH, REZDIFFRA, RINVOQ, VEGZELMA, Sucraid, SKYRIZI.
Industry payments across TX — which companies pay providers there.
